Christian Wider
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Christian Wider has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Owen A. Ross
Department of Neuroscience, Mayo Clinic , Jacksonville, FL 32224
3 shared publications A. Tselis
2 shared publicationsB. Ghetti
2 shared publicationsC. Sundal
2 shared publications- Carles Vilariño-Güell
Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada
2 shared publications D. Broderick
2 shared publications
Latest Publications
- 8 December 2015
- Published by Wolters Kluwer Health in Neurology
- Vol. 85 (23) , 2002-2003
Rare genetic variants support mitochondrial dysfunction in Lewy body disorders
- 8 December 2015
- Published by Wolters Kluwer Health in Neurology
- Vol. 85 (23) , 2002-2003
Rare genetic variants support mitochondrial dysfunction in Lewy body disorders
- Open Access
- 16 April 2015
- Published by Springer Nature in BMC Neurology
- Vol. 15 (1) , 1-4
PTPN11 mutation manifesting as LEOPARD syndrome associated with hypertrophic plexi and neuropathic pain
LEOPARD syndrome (LS) belongs to the family of neuro-cardio-facio-cutaneous syndromes, which include Neurofibromatosis-1 (NF1), Noonan syndrome, Costello Syndrome, cardio-facio-cutaneous syndrome, Noonan-like syndrome with loose anagen hair and Legius syndrome. These conditions are caused by mutations in genes encoding proteins involved in the RAS-MAPK cellular pathway. Clinical heterogeneity and phenotype overlaps across those different syndromes is already recognized. We hereby report a heterozygous de novo mutation in the PTPN11 gene (c.1403C > T) manifesting with a clinical picture of LS during childhood, and later development of neuropathic pain with hypertrophic plexi, which are typically observed in NF1 but have not been reported in LS. LS caused by PTPN11 mutations may be associated with hypertrophic roots and plexi. Consequently, clinicians should be aware of the possible development of neuropathic pain and consider specific diagnostic work-up and management.
- 16 April 2015
- Published by Springer Nature in BMC Neurology
- Vol. 15 (1) , 1-4
Open AccessPTPN11 mutation manifesting as LEOPARD syndrome associated with hypertrophic plexi and neuropathic pain
LEOPARD syndrome (LS) belongs to the family of neuro-cardio-facio-cutaneous syndromes, which include Neurofibromatosis-1 (NF1), Noonan syndrome, Costello Syndrome, cardio-facio-cutaneous syndrome, Noonan-like syndrome with loose anagen hair and Legius syndrome. These conditions are caused by mutations in genes encoding proteins involved in the RAS-MAPK cellular pathway. Clinical heterogeneity and phenotype overlaps across those different syndromes is already recognized. We hereby report a heterozygous de novo mutation in the PTPN11 gene (c.1403C > T) manifesting with a clinical picture of LS during childhood, and later development of neuropathic pain with hypertrophic plexi, which are typically observed in NF1 but have not been reported in LS. LS caused by PTPN11 mutations may be associated with hypertrophic roots and plexi. Consequently, clinicians should be aware of the possible development of neuropathic pain and consider specific diagnostic work-up and management.
- 1 March 2014
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 20 (3) , 351-352
GNAL deletion as a probable cause of dystonia in a patient with the 18p- syndrome
- 1 March 2014
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 20 (3) , 351-352
GNAL deletion as a probable cause of dystonia in a patient with the 18p- syndrome
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , P06.180
Observational Study for MRI Characteristics in HDLS with a Known Gene Mutation on Chromosome 5 (P06.180)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , P06.180
Observational Study for MRI Characteristics in HDLS with a Known Gene Mutation on Chromosome 5 (P06.180)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , P05.119
HDLS: Due to CSF1R Gene Mutation; Clinical Characteristics (P05.119)
- 22 April 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (Meeting Ab) , P05.119
HDLS: Due to CSF1R Gene Mutation; Clinical Characteristics (P05.119)
- 15 December 2010
- Published by Wiley in European Journal of Neurology
- Vol. 18 (6) , 876-881
SNCA,MAPT, andGSK3Bin Parkinson disease: a gene-gene interaction study
Background and purpose: Recent evidence suggests that variation in the SNCA, MAPT, and GSK3B genes interacts in affecting risk for Parkinson disease (PD). In the current study, we attempt to validate previously published findings, evaluating gene–gene interactions between SNCA, MAPT, and GSK3B in association with PD. Methods: Three Caucasian PD patient–control series from the United States, Ireland, and Norway (combined n = 1020 patients and 1095 controls) were genotyped for SNCA rs356219, MAPT H1/H2‐discriminating SNP rs1052553, and GSK3B rs334558 and rs6438552. Results: Our findings indicate that as previously reported, the SNCA rs356219‐G allele and MAPT rs1052553 (H1 haplotype) were both associated with an increased risk of PD, whilst contrary to previous reports, GSK3B variants were not. No pair‐wise interaction was observed between SNCA, MAPT, and GSK3B; the risk effects of SNCA rs356219‐G and MAPT rs1052553‐H1 were seen in a similar manner across genotypes of other variants, with no evidence suggesting synergistic, antagonistic, or deferential effects. Conclusions: In the Caucasian patient–control series examined, risk for PD was influenced by variation in SNCA and MAPT but not GSK3B. Additionally, those three genes did not interact in determining disease risk.
- 15 December 2010
- Published by Wiley in European Journal of Neurology
- Vol. 18 (6) , 876-881
SNCA,MAPT, andGSK3Bin Parkinson disease: a gene-gene interaction study
Background and purpose: Recent evidence suggests that variation in the SNCA, MAPT, and GSK3B genes interacts in affecting risk for Parkinson disease (PD). In the current study, we attempt to validate previously published findings, evaluating gene–gene interactions between SNCA, MAPT, and GSK3B in association with PD. Methods: Three Caucasian PD patient–control series from the United States, Ireland, and Norway (combined n = 1020 patients and 1095 controls) were genotyped for SNCA rs356219, MAPT H1/H2‐discriminating SNP rs1052553, and GSK3B rs334558 and rs6438552. Results: Our findings indicate that as previously reported, the SNCA rs356219‐G allele and MAPT rs1052553 (H1 haplotype) were both associated with an increased risk of PD, whilst contrary to previous reports, GSK3B variants were not. No pair‐wise interaction was observed between SNCA, MAPT, and GSK3B; the risk effects of SNCA rs356219‐G and MAPT rs1052553‐H1 were seen in a similar manner across genotypes of other variants, with no evidence suggesting synergistic, antagonistic, or deferential effects. Conclusions: In the Caucasian patient–control series examined, risk for PD was influenced by variation in SNCA and MAPT but not GSK3B. Additionally, those three genes did not interact in determining disease risk.
- 30 November 2010
- Published by Wiley in European Journal of Neurology
- Vol. 18 (8) , 1090-1093
Death-associated protein kinase 1 variation and Parkinson’s disease
- 30 November 2010
- Published by Wiley in European Journal of Neurology
- Vol. 18 (8) , 1090-1093
Death-associated protein kinase 1 variation and Parkinson’s disease
- 1 August 2010
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 23 (4) , 388-393
Genetics of Parkinson disease and essential tremor
Elucidating the genetic background of Parkinson disease and essential tremor is crucial to understand the pathogenesis and improve diagnostic and therapeutic strategies. A number of approaches have been applied including familial and association studies, and studies of gene expression profiles to identify genes involved in susceptibility to Parkinson disease. These studies have nominated a number of candidate Parkinson disease genes and novel loci including Omi/HtrA2, GIGYF2, FGF20, PDXK, EIF4G1 and PARK16. A recent notable finding has been the confirmation for the role of heterozygous mutations in glucocerebrosidase (GBA) as risk factors for Parkinson disease. Finally, association studies have nominated genetic variation in the leucine-rich repeat and Ig containing 1 gene (LINGO1) as a risk for both Parkinson disease and essential tremor, providing the first genetic evidence of a link between the two conditions. Although undoubtedly genes remain to be identified, considerable progress has been achieved in the understanding of the genetic basis of Parkinson disease. This same effort is now required for essential tremor. The use of next-generation high-throughput sequencing and genotyping technologies will help pave the way for future insight leading to advances in diagnosis, prevention and cure.
- 1 August 2010
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 23 (4) , 388-393
Genetics of Parkinson disease and essential tremor
Elucidating the genetic background of Parkinson disease and essential tremor is crucial to understand the pathogenesis and improve diagnostic and therapeutic strategies. A number of approaches have been applied including familial and association studies, and studies of gene expression profiles to identify genes involved in susceptibility to Parkinson disease. These studies have nominated a number of candidate Parkinson disease genes and novel loci including Omi/HtrA2, GIGYF2, FGF20, PDXK, EIF4G1 and PARK16. A recent notable finding has been the confirmation for the role of heterozygous mutations in glucocerebrosidase (GBA) as risk factors for Parkinson disease. Finally, association studies have nominated genetic variation in the leucine-rich repeat and Ig containing 1 gene (LINGO1) as a risk for both Parkinson disease and essential tremor, providing the first genetic evidence of a link between the two conditions. Although undoubtedly genes remain to be identified, considerable progress has been achieved in the understanding of the genetic basis of Parkinson disease. This same effort is now required for essential tremor. The use of next-generation high-throughput sequencing and genotyping technologies will help pave the way for future insight leading to advances in diagnosis, prevention and cure.
- 3 May 2006
- Vol. 2 (64) , 1158-62
[Neuronal death and growth factors: new therapeutic approaches in Parkinson's disease].
Neurodegenerative disorders represent a major and growing cause of morbidity and mortality in our populations, and a therapeutic challenge for the years to come. This paper reviews the mechanisms implicated in neuronal death, focusing on the model of Parkinson's disease. Available data are critically presented, and oriented in a therapeutic perspective. Neuroprotective strategies are mentioned, along with stem cell transplantation, growth factor production and gene therapy.
- 3 May 2006
- Vol. 2 (64) , 1158-62
[Neuronal death and growth factors: new therapeutic approaches in Parkinson's disease].
Neurodegenerative disorders represent a major and growing cause of morbidity and mortality in our populations, and a therapeutic challenge for the years to come. This paper reviews the mechanisms implicated in neuronal death, focusing on the model of Parkinson's disease. Available data are critically presented, and oriented in a therapeutic perspective. Neuroprotective strategies are mentioned, along with stem cell transplantation, growth factor production and gene therapy.